NeuroGenesis Bio
Private Company
Funding information not available
Overview
NeuroGenesis Bio is a private, clinical-stage biotechnology company based in San Diego, CA, founded in 2007. The company is developing the NG CELL™ platform, an autologous cell therapy designed to deliver sustained levels of therapeutic proteins directly to the central nervous system to repair damage in progressive MS and ALS. With a seasoned leadership team experienced in cell therapy development and neurology, NeuroGenesis is advancing its lead programs through clinical trials. The company operates as a pre-revenue therapeutics developer targeting significant unmet needs in neurodegenerative diseases.
Technology Platform
NG CELL™ platform: A proprietary autologous cell therapy where a specific subpopulation of a patient's bone marrow stem cells is selected, enhanced to become 'biofactory' cells, and injected intrathecally to produce sustained levels of remyelinating and neuroprotective proteins (e.g., CNTF, BDNF) directly in the CNS.
Opportunities
Risk Factors
Competitive Landscape
NeuroGenesis competes in the neurodegenerative disease space with large pharma (e.g., Biogen, Roche) and biotechs developing small molecules, antibodies, and gene therapies. In cell therapy for MS/ALS, direct competitors are few but include companies like Lineage Cell Therapeutics and BrainStorm Cell Therapeutics, though their technological approaches differ. The autologous, 'biofactory' mechanism is a key differentiator.